| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
CCR4 0.02 μM (IC50)
CCR4 antagonist 4 targets the CC chemokine receptor 4 (CCR4), a G protein-coupled receptor involved in the recruitment of immune cells, particularly Th2 cells, to sites of inflammation. By blocking CCR4, this compound inhibits the signaling pathways that lead to chemotaxis and activation of these cells. |
|---|---|
| ln Vitro |
In vitro, CCR4 antagonist 4 potently inhibits CCR4 with an IC50 of 0.02 μM. It also blocks MDC-mediated chemotaxis with an IC50 of 0.007 μM and Ca2+ mobilization with an IC50 of 0.003 μM. These activities demonstrate its high potency and efficacy in blocking CCR4-mediated signaling.
|
| ln Vivo |
In vivo, CCR4 antagonist 4 is used for research into allergic inflammation. By blocking CCR4, it is expected to reduce the recruitment of Th2 cells and the subsequent inflammatory response in animal models of allergy. Specific animal model data are not detailed in the provided literature.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assay protocols for CCR4 antagonist 4 typically involve radioligand binding assays to determine its affinity for CCR4. Functional assays, such as measuring MDC-induced chemotaxis or Ca2+ mobilization in cells expressing CCR4, are used to assess its antagonist activity.
|
| Cell Assay |
In vitro cell-based assay protocols for CCR4 antagonist 4 involve using cells that express CCR4, such as primary immune cells or cell lines. Cells are treated with the compound and then stimulated with a CCR4 agonist (e.g., MDC) to induce chemotaxis or calcium flux. The inhibition of these responses is measured to determine the compound's potency.
|
| Animal Protocol |
In vivo animal experimental protocols for CCR4 antagonist 4 would typically involve using mouse models of allergic inflammation, such as asthma or atopic dermatitis. The compound is administered, and endpoints such as inflammatory cell infiltration, cytokine levels, and clinical symptoms are evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CCR4 antagonist 4 have not been characterized in published studies. Specific parameters such as half-life, Cmax, and bioavailability have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for CCR4 antagonist 4 are limited. It is intended for research use only. As a research chemical, standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
CCR4 receptor antagonists
CCR4 antagonist 4 is a research-grade compound used as a potent and selective antagonist of the CCR4 receptor for studying allergic inflammation. It has not entered clinical trials and is not approved for any therapeutic indication. Its mechanism of action involves blocking CCR4-mediated chemotaxis and signaling. The compound is available exclusively for research purposes. |
| Molecular Formula |
C24H27CL2N7O
|
|---|---|
| Molecular Weight |
500.423482179642
|
| Exact Mass |
499.165
|
| CAS # |
668980-17-4
|
| PubChem CID |
9827294
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
34
|
| Complexity |
680
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CCN[C@H](C1)C(=O)N2CCN(CC2)C3=NC4=C(C=CC=N4)C(=N3)NCC5=C(C=C(C=C5)Cl)Cl
|
| InChi Key |
GDQQUDANFRCFMF-HXUWFJFHSA-N
|
| InChi Code |
InChI=1S/C24H27Cl2N7O/c25-17-7-6-16(19(26)14-17)15-29-22-18-4-3-9-28-21(18)30-24(31-22)33-12-10-32(11-13-33)23(34)20-5-1-2-8-27-20/h3-4,6-7,9,14,20,27H,1-2,5,8,10-13,15H2,(H,28,29,30,31)/t20-/m1/s1
|
| Chemical Name |
[4-[4-[(2,4-dichlorophenyl)methylamino]pyrido[2,3-d]pyrimidin-2-yl]piperazin-1-yl]-[(2R)-piperidin-2-yl]methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :≥ 100 mg/mL (~199.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300 and mix well. Then add 50 μL Tween-80 to the above system and mix well. Then continue to add 450 μL of physiological saline to make up to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9983 mL | 9.9916 mL | 19.9832 mL | |
| 5 mM | 0.3997 mL | 1.9983 mL | 3.9966 mL | |
| 10 mM | 0.1998 mL | 0.9992 mL | 1.9983 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
